Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04571697 · ClinicalTrials.gov registry record
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 34,647
- Enrollment target
NCT04571697: Completed study, sponsored by Janssen Research & Development.
NCT04571697 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 34,647 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04571697 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 34,647 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the risk of dementia in participants diagnosed with rheumatoid arthritis (RA) exposed to anti-tumor necrosis factor (TNF) therapy versus those exposed to methotrexate.
Primary Outcome
An outcome of dementia requires at least two diagnosis codes international classification of diseases, ninth revision, clinical modification (ICD-9-CM) or international classification of diseases, tenth revision, clinical modification (ICD-10-CM) for dementia within 365 days of each other.
Interventions
- DRUG Methotrexate
- DRUG Anti-TNF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34,647 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2020-10-27 |
What the finished NCT04571697 record still lists
NCT04571697 is an observational study that tracks outcomes without assigning an intervention. Its 34,647 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.
NCT04571697 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04571697 about?
NCT04571697 is a clinical study titled "A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy". The purpose of the study is to compare the risk of dementia in participants diagnosed with rheumatoid arthritis (RA) exposed to anti-tumor necrosis factor (TNF) therapy versus those exposed to methotrexate.
What is the current status of trial NCT04571697?
This trial is currently completed. The enrollment target is 34,647 participants. The study started on 2020-09-28. Estimated completion is 2020-10-27.
What interventions are being tested in trial NCT04571697?
The interventions under investigation include: Methotrexate (DRUG), Anti-TNF (DRUG).
Who is sponsoring clinical trial NCT04571697?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT06145724 · 33,183 participants · NA
EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI